DiaSource Award ! Best in vitro diagnostic solutions provider in Europe 2024. Find out more...
DiaSource, with over 30 years of experience in the diagnostic field, stands at the forefront of the global healthcare industry. The company's mission is clear—to provide reliable and affordable diagnostics solutions to patients worldwide. Operating through a global distribution network, the firm ensures that everyone has access to the best possible care.
"Our ambition is to offer first-in-class diagnostic products," states Béatrice de Borman, CEO. “We believe that better diagnostics lead to better treatments." The company also shares its proprietary antibodies with other IVD manufacturers, facilitating the development of advanced assays on various platforms and significantly enhancing patient access to state-of-the-art healthcare solutions.
DiaSource develops and manufactures clinical diagnostic products. It focuses on various diagnostic technologies, including ELISA, RIA, CLIA and BLOT reactions. This enables the company to cover multiple disease fields, such as endocrinology, allergy and infectious diseases.
DiaSource offers an array of in vitro diagnostic (IVD) instruments, from manual to fully automated systems. Whether it's radioactive, colorimetric, or chemiluminescence instruments, it analyzes each clinical laboratory’s needs to tailor its offerings to the lab's throughput and energy requirements. This customisation is one of the reasons why DiaSource has established itself as a preferred partner for healthcare providers.
Commitment to Technological Innovations
From the outset, DiaSource has focused on endocrinology, developing and producing antibodies against small molecules like steroids.
"Our first and core business was the production and development of antibodies against steroids due to their complexity and essential role in diagnosing conditions ranging from fertility issues to cancer and diabetes," says de Borman. The company continued to expand into cancer markers, promoting the early diagnosis and treatment of cancer that led to a significant improvement in patient survival rates.
Another significant area of development for DiaSource is in infectious diseases. It offers comprehensive kits that analyze the immune response to diagnose and differentiate stages of infection. These kits determine whether the patient is currently or has previously been infected, as well as to identify their stage in the recovery process.
DiaSource began its technological journey by focusing on radioimmunoassay (RIA)—which remains a foundational aspect of its business. It has since used colorimetric methods to enter the enzyme-linked immunosobent assay (ELISA) field, later expanding into chemiluminescent immunoassay (CLIA). This progression underscores its commitment to evolve and provide user-friendly, automated solutions that adapt to clinical laboratory’s changing requirements.
Placing People at the Heart of the Company
DiaSource's commitment extends beyond profit; it aims to make a difference in regions where healthcare is most needed. The company has made significant efforts to provide diagnostics to countries with economic and geopolitical concerns. Despite the halt in global air travel during the COVID-19 pandemic, it was among the few companies that continued operations and ensured that diagnostics reached those in need.
In addition, its ISO 9001 and ISO 13485 certifications ensure that its customer service and manufacturing processes meet stringent quality criteria. DiaSource also holds Medical Device Single Audit Program (MDSAP) certification, demonstrating its compliance with medical device quality requirements in major markets, including the U.S., Canada, Australia and Japan. Its products have registrations in more than 50 countries, including the Food and Drug Administration (FDA), Korean Good Manufacturing Practice (KGMP) and the Pharmaceuticals and Medical Devices Agency (PMDA).
DiaSource has cemented its position as a reliable partner in the diagnostics sector. Its success can be attributed mainly to its team, with each employee focusing on customer services, regulatory affairs, production and QA/QC. Its ongoing partnerships with universities and clinical laboratories underscore its dedication to diagnostic innovation and advancement.
Looking ahead, the company remains committed to bringing life-changing diagnostics to those in need, advocating for broader access and continuous improvement in patient care. DiaSource is not just creating diagnostics; it is shaping a future where every patient has access to the best healthcare.
Article in collaboration with MedTech Outlook Magazine.
Learn more about the article :
DiaSource-Top In vitro Diagnostic Solutions Providers in Europe 2024.
